New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
10:04 EDTSYK, TRNX, JNJ, IART, ZMH, SNN, WMGIVolume trends from CCJR meeting positive for Zimmer, says Piper Jaffray
Piper Jaffray said it has more confidence in improving volume trends in the orthopedic market following its attendance at the Current Concepts in Joint Replacement meeting, which it views as particularly positive for Zimmer (ZMH). The firm also said the trends and expectations pointed to at the meeting were positive, but to a lesser extent, for Tornier (TRNX), Wright Medical (WMGI), Integra LifeSciences (IART), Stryker (SYK), Smith & Nephew (SNN) and Johnson & Johnson (JNJ).
News For ZMH;TRNX;WMGI;IART;SYK;SNN;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
February 26, 2015
09:41 EDTJNJHospira launches generic Remicade, WSJ says
Subscribe for More Information
08:03 EDTJNJJohnson & Johnson forms new health and wellness platform
Subscribe for More Information
06:52 EDTJNJPharmacyclics downgraded to Hold from Buy at WallachBeth
Subscribe for More Information
February 25, 2015
17:50 EDTWMGIWright Medical sees FY15 adjusted EPS ($1.67)-($1.77), consensus (95c)
Subscribe for More Information
17:48 EDTWMGIWright Medical reports Q4 adjusted EPS (25c), consensus (27c)
Reports Q4 revenue $83.3M, consensus $84.01M.
14:47 EDTJNJPharmacyclics could fetch as much as $19B in sale, FT says
Pharmacyclics (PCYC) is considering a sale that could fetch as much as $19B, reported Financial Times, citing people familiar with the matter who said Johnson & Johnson (JNJ) is exploring a potential deal for the company. The Fly notes that Bloomberg had a similar report, but its report said Pharmacyclics could fetch $17B-$18B in a sale. Reference Link
14:10 EDTJNJPharmacyclics downgraded to Hold on lack of upside at Deutsche Bank
Subscribe for More Information
12:54 EDTJNJPharmacyclics exploring options including sale, Bloomberg reports
According to sources, Pharmacyclics (PCYC), which develops cancer treatments, is currently exploring options, Bloomberg reports. One option may include a sale of the company, and the sources say Johnson & Johnson (JNJ) and Novartis (NVS) have expressed interest in the company. Pharmacyclics could fetch $17B-$18B in a sale, the sources add. Reference Link
12:53 EDTJNJPharmacyclics weighing sale to U.S. drugmaker, Bloomberg reports
Subscribe for More Information
February 24, 2015
16:11 EDTTRNXTornier sees FY15 EPS (65c)-(38c), consensus (38c)
Subscribe for More Information
16:09 EDTTRNXTornier reports Q4 EPS (17c), consensus (11c)
Subscribe for More Information
06:32 EDTIARTIntegra LifeSciences sees FY15 adjusted EPS $3.05-$3.23, consensus $3.27
Subscribe for More Information
06:32 EDTIARTIntegra LifeSciences reports Q4 adjusted EPS 94c, consensus 89c
Subscribe for More Information
February 23, 2015
10:18 EDTIARTIntegra LifeSciences management to meet with JMP Securities
Subscribe for More Information
February 22, 2015
12:51 EDTJNJJ&J considers Cordis sale with Cardinal the leading suitor, Bloomberg says
Subscribe for More Information
February 20, 2015
17:31 EDTJNJJ&J considering sale of Cordis with Cardinal the leading suitor, Bloomberg says
Subscribe for More Information
16:03 EDTJNJOptions Update; February 20, 2015
Subscribe for More Information
09:38 EDTJNJActive equity options trading on open
Subscribe for More Information
08:27 EDTSYKStryker has a conference call hosted by JPMorgan
Subscribe for More Information
07:23 EDTJNJAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use